Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AAL stock price vs BMRN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Needs BMRN P/E.
Implied fair value · at AAL's multiple
Needs AAL P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AAL FY 2025 (ended Dec 31, 2025) · BMRN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 24% equity / 76% debt · EV / Revenue 0.66x · EV / EBITDA 19.10x
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
AAL carries the larger enterprise value at $36.02B against $12.07B; AAL trades on the lower EV / Revenue multiple (0.66x vs 3.75x); AAL on the lower EV / EBITDA (19.10x vs 21.37x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
American Airlines Group Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-7.59x
0.08x
Net debt / EBITDA
Leverage against operating earnings
14.49x
-1.43x
Cash and equivalents
Liquid reserves on the balance sheet
$954.00M
$1.31B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
DELTA AIR LINES, INC.
AAL vs DAL
SOUTHWEST AIRLINES CO
AAL vs LUV
GENWORTH FINANCIAL INC
AAL vs GNW
United Airlines Holdings, Inc.
AAL vs UAL
VERTEX PHARMACEUTICALS INC / MA
AAL vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
AAL vs ALNY
Sarepta Therapeutics, Inc.
AAL vs SRPT
REGENXBIO Inc.
AAL vs RGNX
IONIS PHARMACEUTICALS INC
AAL vs IONS
PTC THERAPEUTICS, INC.
AAL vs PTCT
$28.28B
$505.32M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
